Phase 1/2a, randomised, double-blinded, placebo-controlled, dose- escalation study

Phase 1/2a, randomised, double-blinded, placebo-controlled, dose- escalation study to evaluate the safety, tolerability, Immunogenicity and vaccine-like viral shedding of MEDI-534, a live, attenuated intranasal vaccine against respiratory syncytical virus (RSV) and parainfluenza virus type 3 (PIV 3), in healthy 6 - <24 month-old children in and 2 month old infants


RSV and PIV3 are important causes of bronchiolitis (inflammation of the small airways in the lungs) and pneumonia in infants and young children. 


The purpose of this study is to describe the safety, immune response (ability of the body to fight infection), and virus shedding (virus that can be found in the nose after vaccination) of an experimental live PIV3 and RSV nasal vaccine called MEDI 534 in comparison to a placebo (an inactive sugar and salt solution that does not contain the vaccine, MEDI-534).  MEDI -534 or placebo is given as nose drops in this study.

Recruitment for this study was completed in 2011, all subjects have received there last dose of Investigational Product.  The study is in phone call follow up of which the last calls will take place in October 2012.  The Vaccines Trials Group recruited 4 participants to this study.  All visits and phone call follow ups were completed in January 2012. 

Funders of the project - MedImmune

Team Members

Dr Peter Richmond, Dr Tanya Stoney

Subscribe to our e-news

Mailing list terms and Conditions

By subscribing to this service you are giving Telethon Kids Institute permission to contact you direct via email. You may unsubscribe at anytime via the emails sent to you.

Your email address will not be disclosed to any third party.

Please agree with the Terms & Conditions.